Targeted therapies have greatly improved patient outcomes over the past 20 years.
This review summarizes current utilization of anti-HER2 targeted therapy across several non-breast solid tumors in the setting of advanced disease.
The study findings signal the need for improved equality in PrEP prescribing across various institutions and settings.
The process of supporting a cause for our profession can be highly rewarding. As pharmacists, we must take charge to enact change.
Leaders Must Continue to Prioritize Empathy and Human Connection.
Pharmacists are critically important in care delivery in their ability to influence patient success, patient-reported outcomes, and quality of life while reducing the burden on physicians and their clinical support teams.
Pharmacists need to ensure anticoagulants are held appropriately before and after surgery to prevent complications from for CIED infections.
The multiple myeloma landscape is evolving, with bispecific T-cell engagers offering hope.
Intranasal decongestants are preferred alternatives to oral phenylephrine for relief of nasal congestion.
The health care industry must cultivate volunteer support to maintain a positive impact on vaccination rates.
This inflammation of the colon poses a substantial burden to patients and the health care system.
Patient fears can be mitigated by pharmacists who use targeted communication strategies to bolster acceptance.
When helping individuals prepare for travel, pharmacists must make travel health recommendations and know common travel-related immunizations and additional resources.
Pharmacists play a vital role in HIV care by addressing social determinants of health, managing complex HIV medication regimens, and providing comprehensive patient counseling.
In business, growth for the sake of growth mirrors the ideology of the cancer cell.
Panelists discuss how the initiation of statin therapy requires careful consideration of contraindications and patient-specific factors, particularly in those with liver disease, renal impairment, or advanced age, while noting evolving treatment patterns toward more intensive low-density lipoprotein cholesterol (LDL-C)–lowering therapies based on individualized risk assessment.
The combination of loop diuretics with other drugs that act at different pharmacologic targets has been shown to improve diuretic response in patients with heart failure.
This article reviews the efficacy and safety data for bispecific T-cell engagers and the practical considerations for their implementation across various types of practice sites for the historically difficult-to-treat relapsed/refractory B-cell lymphoma population.
Gold bagging integrates health system-owned specialty pharmacies with clinical workflows to enhance safety, efficiency, outcomes, and patient experience.
Closing out their discussion on Clostridioides difficile infection, panelists share closing thoughts on novel pipeline therapies.
Pharmacists should get involved in all the various aspects of their business and with the different professional groups available.
Investigators assessed the efficacy of BsAb5003 in treating multiple myeloma, with the results showing that the therapy may be an effective treatment approach.
Experts share operational challenges and patient care implications of the Inflation Reduction Act's (IRA) drug pricing reforms.
Axatilimab is a colony-stimulating factor-1 receptor–blocking monoclonal antibody indicated after 2 lines of systemic therapy.
For pharmacists wondering whether bismuth quadruple therapy still reigns as the gold standard, the wait is over—the latest recommendations are here.
The hybrid pharmacy model represents a significant step forward in providing the best possible care for individuals struggling with behavioral health conditions, ultimately improving their outcomes and overall well-being.
Pharmacists with a deeper knowledge of xerostomia are ideally positioned to help educate patients with dry mouth on making informed self-care decisions for effective symptom management and improved quality of life.
Confusing product labeling and conflicting data can create challenges for patients.
For more than 30 years, there has been little treatment advancement for NMIBC patients. Fortunately, a new development in the treatment of NMIBC has been approved by the FDA and is now available.
Empathy is being left outside the exam room door.